{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:10:10Z","timestamp":1778962210851,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K02DA032322"],"award-info":[{"award-number":["K02DA032322"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R61\/R33 DA047037"],"award-info":[{"award-number":["R61\/R33 DA047037"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.conctc.2021.100866","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:07:41Z","timestamp":1636632461000},"page":"100866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence"],"prefix":"10.1016","volume":"24","author":[{"given":"Alysse","family":"Schultheis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savannah","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8913-108X","authenticated-orcid":false,"given":"Tassos","family":"Kyriakides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Chi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6318-1000","authenticated-orcid":false,"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2021.100866_bib2","series-title":"State Of the Epidemic. Geneva 2019","year":"2019"},{"key":"10.1016\/j.conctc.2021.100866_bib3","unstructured":"Costa AM. Reducing the Adverse Health and Social Consequences of Drug Abuse: a comprehensive approach2008:1-9, Vienna."},{"key":"10.1016\/j.conctc.2021.100866_bib4","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.drugpo.2005.02.008","article-title":"Effectiveness of drug dependence treatment in HIV prevention. International Journal of Drug Policy","volume":"16S","author":"Farrell","year":"2005","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.conctc.2021.100866_bib5","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, Opioid Dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study","volume":"56","author":"Altice","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"5","key":"10.1016\/j.conctc.2021.100866_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.conctc.2021.100866_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11524-010-9438-4","article-title":"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of Buprenorphine treatment","volume":"87","author":"Springer","year":"2010","journal-title":"J. Urban Health"},{"issue":"3","key":"10.1016\/j.conctc.2021.100866_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006283","article-title":"Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir","volume":"13","author":"Bui","year":"2017","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.conctc.2021.100866_bib9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4 + T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics","volume":"214","author":"Hosmane","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.conctc.2021.100866_bib10","first-page":"113","article-title":"Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA","volume":"49","author":"Lorenzi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6128","key":"10.1016\/j.conctc.2021.100866_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/328345a0","article-title":"HIV-specific cytotoxic T lymphocytes in seropositive individuals","volume":"328","author":"Walker","year":"1987","journal-title":"Nature"},{"issue":"6198","key":"10.1016\/j.conctc.2021.100866_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/336484a0","article-title":"HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides","volume":"336","author":"Nixon","year":"1988","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.conctc.2021.100866_bib13","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.4049\/jimmunol.173.8.5305","article-title":"Increased natural killer cell activity in viremic HIV-1 infection","volume":"173","author":"Alter","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.conctc.2021.100866_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0028-3908(90)90096-A","article-title":"Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism","volume":"29","author":"Bayer","year":"1990","journal-title":"Neuropharmacology"},{"issue":"4914","key":"10.1016\/j.conctc.2021.100866_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1126\/science.2749256","article-title":"The periaqueductal gray matter mediates opiate-induced immunosuppression","volume":"245","author":"Weber","year":"1989","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.conctc.2021.100866_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0022-3565(25)38754-9","article-title":"Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice","volume":"269","author":"Carr","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"11","key":"10.1016\/j.conctc.2021.100866_bib17","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1073\/pnas.95.11.6326","article-title":"Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene","volume":"95","author":"Gav\u00e9riaux-Ruff","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.conctc.2021.100866_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0376-8716(01)00171-5","article-title":"Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis","volume":"65","author":"Farr\u00e9","year":"2002","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.conctc.2021.100866_bib19","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1086\/317615","article-title":"Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection","volume":"182","author":"Blankson","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.conctc.2021.100866_bib20","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1172\/JCI120194","article-title":"HIV-1 latent reservoir size and diversity are stable following brief treatment interruption","volume":"128","author":"Salantes","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.conctc.2021.100866_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006792","article-title":"Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals","volume":"14","author":"Clarridge","year":"2018","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.conctc.2021.100866_bib22","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/infdis\/jiaa634","article-title":"Non-structured treatment interruptions are associated with higher HIV reservoir size measured by intact proviral DNA assay in people who inject drugs","volume":"223","author":"Kirk","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.conctc.2021.100866_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inf."},{"issue":"RR-14","key":"10.1016\/j.conctc.2021.100866_bib25","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.conctc.2021.100866_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.janxdis.2020.102274","article-title":"COVID-19 stress and substance use: current issues and future preparations","volume":"74","author":"McKay","year":"2020","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.conctc.2021.100866_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108176","article-title":"Signal of increased opioid overdose during COVID-19 from emergency medical services data","volume":"214","author":"Slavova","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.conctc.2021.100866_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","article-title":"COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States","volume":"26","author":"Wang","year":"2021","journal-title":"Mol. Psychiatr."},{"issue":"7","key":"10.1016\/j.conctc.2021.100866_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.conctc.2021.100866_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2013II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.conctc.2021.100866_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.conctc.2021.100866_bib32","series-title":"The Alcohol, Smoking and Substance involvement Screening Test (ASSIST): manual for use in primary care","author":"Organization Wh","year":"2010"},{"key":"10.1016\/j.conctc.2021.100866_bib33","series-title":"The Reliability of the Timeline Followback Method Applied to Drug, Cigarette, and Cannabis Use. 30th Annual Meeting of the Association for Advancement of Behavior Therapy","author":"Sobell","year":"1996"},{"issue":"6","key":"10.1016\/j.conctc.2021.100866_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.15288\/jsa.1998.59.681","article-title":"Self-reports of alcohol use, drug use and sexual behavior: expanding the Timeline Follow-back technique","volume":"59","author":"Midanik","year":"1998","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.conctc.2021.100866_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients","author":"McHugh","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"9","key":"10.1016\/j.conctc.2021.100866_bib36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.conctc.2021.100866_bib37","first-page":"351","article-title":"Development of the world health organization WHOQOL-BREF quality of life assessment. The WHOQOL group","volume":"28","author":"Group WHOQoL","year":"1998","journal-title":"Psychol. Med."},{"key":"10.1016\/j.conctc.2021.100866_bib38","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.conctc.2021.100866_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.conctc.2021.100866_bib40","unstructured":"Feng WW, Jun Y, Xu R. A method\/macro based on propensity score and Mahalanobis distance to reduce bias in treatment comparison in observational study 2005."},{"issue":"8","key":"10.1016\/j.conctc.2021.100866_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.conctc.2021.100866_bib42","series-title":"Analysis of Longitudinal Data","author":"Diggle","year":"1994"},{"key":"10.1016\/j.conctc.2021.100866_bib43","series-title":"Generalized, Linear And Mixed Models","author":"McCulloch","year":"2001"},{"key":"10.1016\/j.conctc.2021.100866_bib44","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"2002"},{"issue":"1","key":"10.1016\/j.conctc.2021.100866_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap methods: another look at the jackknife","volume":"7","author":"Efron","year":"1979","journal-title":"Ann. Stat."},{"key":"10.1016\/j.conctc.2021.100866_bib46","article-title":"Multiple comparisons and multiple tests using SAS","author":"Westfall","year":"2011"},{"issue":"1","key":"10.1016\/j.conctc.2021.100866_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"issue":"101118","key":"10.1016\/j.conctc.2021.100866_bib48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.conctc.2021.100866_bib49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1037\/adb0000010","article-title":"Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes","volume":"29","author":"Dunn","year":"2015","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.conctc.2021.100866_bib50","first-page":"14","article-title":"Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs","volume":"645","author":"Hayes","year":"2014","journal-title":"BMC Publ. Health"},{"issue":"5","key":"10.1016\/j.conctc.2021.100866_bib51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010","volume":"160","author":"Denniston","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.conctc.2021.100866_bib52","series-title":"Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine","author":"Gladden","year":"2019"},{"key":"10.1016\/j.conctc.2021.100866_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addbeh.2019.04.022","article-title":"The epidemiology of prescription fentanyl misuse in the United States","volume":"96","author":"Schepis","year":"2019","journal-title":"Addict. Behav."},{"key":"10.1016\/j.conctc.2021.100866_bib54","series-title":"HIV Infection And HIV-Associated Behaviors Among Persons Who Inject Drugs \u2014 20 Cities","author":"Burnett","year":"2015"},{"issue":"6","key":"10.1016\/j.conctc.2021.100866_bib55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/QAD.0000000000001039","article-title":"Kerr T, carrieri P, feelemyer J, arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks","volume":"30","author":"jarlais DCD","year":"2016","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.conctc.2021.100866_bib56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","article-title":"The syndemic of opioid misuse, overdose, HCV and HIV: structural-level causes and interventions","volume":"15","author":"Perlman","year":"2018","journal-title":"Curr. HIV AIDS Rep."},{"issue":"12","key":"10.1016\/j.conctc.2021.100866_bib57","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.conctc.2021.100866_bib58","series-title":"HIV Surveillance Report, 2018 (Updated)","year":"2020"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:04:27Z","timestamp":1762520667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865421001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":56,"alternative-id":["S2451865421001666"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100866","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100866"}}